GLP-1-Based Pharmacotherapies and Skeletal Muscle Health in Obesity: A Narrative Review of Body Composition, Muscle Function, and Sarcopenia-Related Outcomes
- 1Student Scientific Club of Human Nutrition, Faculty of Health Sciences and Psychology, Collegium Medicum, , ul. Warzywna 1a, 35-959 Rzeszow, Poland; (J.K.); (W.F.)
- 2Departament of Dietetics, Faculty of Health Sciences and Psychology, Collegium Medicum, , ul. Warzywna 1a, 35-959 Rzeszow, Poland
Abstract
Background: Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intramuscular fat may be beneficial. Objective: This narrative review evaluated the effects of GLP-1-based pharmacotherapies on body composition, muscle quantity, composition and function, and their potential role in sarcopenia. Methods: PubMed and Google Scholar were searched for clinical and experimental studies published primarily between 2016 and 2026. Results: Preclinical studies identified potentially protective mechanisms, including improved insulin sensitivity, reduced inflammation, and modulation of mitochondrial function and protein turnover, but some also indicated muscle loss or proteolysis. Clinical studies reported greater reductions in fat mass than in fat-free or lean mass, neither of which represents skeletal muscle exclusively. Direct muscle and functional outcomes were assessed in few studies and yielded mixed results. Incident sarcopenia was rarely evaluated. Conclusions: GLP-1-based pharmacotherapies may influence sarcopenia risk through competing pathways. Metabolic improvements may support muscle health, whereas energy restriction, inadequate protein intake, gastrointestinal adverse effects, and lean tissue loss may increase vulnerability. Current evidence is insufficient to determine their net effect on sarcopenia risk.
Related
- Effects of exercise interventions based on American College of Sports Medicine recommendations on physical function, body composition, and quality of life in older adults with sarcopenia: a meta-analysis of randomized controlled trials
- Magnetomyography for skeletal muscle function assessment: prospective applications in sarcopenia
- A blood test-derived skeletal muscle index combined with handgrip strength identifies a sarcopenia-related high-risk phenotype in non–dialysis-dependent chronic kidney disease
- Sarcopenia and cognitive impairment after hip fracture in older adults: a narrative review and conceptual rehabilitation framework
- Sarcopenia in Hospitalized Patients: A Critical Narrative Review of Diagnostic and Nutritional Management Approaches
BibTeX
@article{knapik2026glp1based,
title = {{GLP-1-Based Pharmacotherapies and Skeletal Muscle Health in Obesity: A Narrative Review of Body Composition, Muscle Function, and Sarcopenia-Related Outcomes}},
author = {Justyna Knapik and Weronika Fic and Ewelina Polak-Szczybyło},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18193247},
url = {https://europepmc.org/article/PMC/PMC13667052},
note = {CC BY},
}
RIS
TY - JOUR
TI - GLP-1-Based Pharmacotherapies and Skeletal Muscle Health in Obesity: A Narrative Review of Body Composition, Muscle Function, and Sarcopenia-Related Outcomes
AU - Justyna Knapik
AU - Weronika Fic
AU - Ewelina Polak-Szczybyło
PY - 2026
DA - 2026/10/01
JO - Nutrients
DO - 10.3390/nu18193247
UR - https://europepmc.org/article/PMC/PMC13667052
AB - Background: Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intramuscular fat may be beneficial. Objective: This narrative review evaluated the effects of GLP-1-based pharmacotherapies on body composition, muscle quantity, composition and function, and their potential role in sarcopenia. Methods: PubMed and Google Scholar were searched for clinical and experimental studies published primarily between 2016 and 2026. Results: Preclinical studies identified potentially protective mechanisms, including improved insulin sensitivity, reduced inflammation, and modulation of mitochondrial function and protein turnover, but some also indicated muscle loss or proteolysis. Clinical studies reported greater reductions in fat mass than in fat-free or lean mass, neither of which represents skeletal muscle exclusively. Direct muscle and functional outcomes were assessed in few studies and yielded mixed results. Incident sarcopenia was rarely evaluated. Conclusions: GLP-1-based pharmacotherapies may influence sarcopenia risk through competing pathways. Metabolic improvements may support muscle health, whereas energy restriction, inadequate protein intake, gastrointestinal adverse effects, and lean tissue loss may increase vulnerability. Current evidence is insufficient to determine their net effect on sarcopenia risk.
SN - 2072-6643
ER -